1. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610.
2. Luo C WC, Osen W, Bosserhoff AK, Eichmüller SB. The role of microRNAsin melanoma. Eur J Cell Biol 2014;93:11-22.
3. A.G. Bader DB, M. Winkler. The promise of microRNA replacement therapy. Cancer research 2010;70: 7027–7030.
4. Völler D, Ott C, Bosserhoff A. MicroRNAs in malignant melanoma. Clin Biochem 2013;46:909-917.
5. Kao CJ MA, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW,et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 2014 May 8;33:2495-2503.
6. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al. MicroRNA‐30a inhibits epithelial‐to‐mesenchymal transition by targeting Snail1 and is downregulated in non‐small cell lung cancer. Int J Cancer Supp 2012;130:2044-2053.
7. He R YL, Lin X, Chen X, Lin X, Wei F, Liang X,et al. MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. Int J Clin Exp Pathol 2015;8:15632-15641.
8. Zhang J, Zhang H, Liu J, Tu X, Zang Y, Zhu J, et al. miR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun 2012;417:1100-1105.
9. Mueller DW RM, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009;129:1740-1751.
10. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, et al. MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 2012;33:732-739.
11. Peinado H OD, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype. Nat Rev Cancer 2007;7:415-428.
12. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, et al. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010;8:27-49.
13. Couts K, Anderson E, Gross M, Sullivan K, Ahn N. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene 2013;32:1959-1970.
14. Mattern J, Volm M. Imbalance of cell proliferation and apoptosis during progression of lung carcinomas. Anticancer Res 2004;24:4243-4246.
15. He R, Yang L, Lin X, Chen X, Lin X, Wei F, et al. MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. Int J Clin Exp Pathol 2015;8:15632–15641.
16. Xie M, Qin H, Luo Q, Huang Q, He X, Yang Z, et al. MicroRNA-30a regulates cell proliferation and tumor growth of colorectal cancer by targeting CD73. BMC cancer 2017;17:305-313.
17. Tsukasa K, Ding Q, Miyazaki Y, Matsubara S, Natsugoe S, Takao S. miR-30 family promotes migratory and invasive abilities in CD133+. Human cell 2016;29:130-1377.
18. Guo L, Zhao RC, Wu Y. The role of microRNAs in self-renewal and differentiation of mesenchymal stem cells. Exp Hematol 2011;39:608-616.
19. Ouzounova M, Vuong T, Ancey P-B, Ferrand M, Durand G, Kelm FL-C, et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC genomics 2013;14:139.
20. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010;29:4194–4204.
21. Zhang Y, Wu Z, Li L, Xie M. miR-30a inhibits glioma progression and stem cell‑like properties by repression of Wnt5a. Oncol Rep 2017;38:1156-1162.
22. Jia Z, Wang K, Wang G, Zhang A, Pu P. MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PloS one 2013;8:e55008.
23. Dixon-McIver A, East P, Mein CA, Cazier J-B, Molloy G, Chaplin T, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PloS one 2008;3:e2141.
24. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer research 2007;67:6130-6135.
25. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-436.
26. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007;26:7590-7595.
27. Yan L-X, Huang X-F, Shao Q, Huang M-Y, Deng L, Wu Q-L, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna 2008;14:2348-2360.
28. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell 2006;9:189-198.
29. Wang W, Lin H, Zhou L, Zhu Q, Gao S, Xie H, et al. MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. EJSO 2014;40:1586-1594.
30. Li W-f, Dai H, Ou Q, Zuo G-q, Liu C-a. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway. Tumour Biol 2016;37:5885-5895.
31. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, et al. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 2014;33:3119-3128.
32. Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, et al. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat 2012;134:1081-1093.
33. Meng F, Wang F, Wang L, Wong SC, Cho WC, Chan LW. MiR-30a-5p overexpression may overcome EGFR-inhibitor resistance through regulating PI3K/AKT signaling pathway in non-small cell lung cancer cell lines. Front Genet 2016;197-206.
34. Wei W, Yang Y, Cai J, Cui K, Li R, Wang H, et al. MiR-30a-5p suppresses tumor metastasis of human colorectal cancer by targeting ITGB3. Cell Physiol Biochem 2016;39:1165-76.